Cyclin dependent kinases in cancer

Figures & data

Figure 1. Cyclin-dependent kinase Inhibitors as possible therapeutic approach for the treatment of cancer. Cell cycle progression through each phase is regulated by cyclin-dependent kinases (CDK) and their regulatory partner proteins, the cyclins. De-regulation of cell-cycle control, due to aberrant CDK activity is a common feature of most cancer types. Specific and selective CDK Inhibitors has been developed as a potential anti-tumor therapeutic approach.

Table 1. First and second generation CDK Inhibitors in ongoing clinical trials

Chemical structure	Name	Generation	Target	Disease	Route administration	Development status
	Flavopiridol	I	CDK2,7,9	Lymphoma/MM	IV	Phase I–III
	R-Roscovitine	I	CDK2,7,9	MM/Lung cancer	oral	Phase I–II
	UCN-01	I	CDK1,2	Leukemia	IV	Phase I
	SNS-032	II	CDK2,7,9	B-malignancies/ MM	IV	Phase I–II
	PD-0332991	II	CDK4,6	Lymphoma/MM/ Breat cancer	oral	Phase I
	P-276–00	II	CDK4/Cyclin D1	Neoplasms	IV	Phase I
	R-547	II	CDK1,2,4	Neoplasms	IV	Phase I–II
	AZD5438	II	CDK1,2	Neoplasms	oral	Phase I
N/A	ZK 304709	II	CDK1,2,4,7,9	Pancreatic tumor	oral	Phase I
	PHA-848125	II	CDK1,2,4,5	Solid Tumors	oral	Phase I–II
	AT7519	II	CDK1,2,4,6,7,9	MM	IV	Phase I–II